These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32636747)

  • 1. Notch Signaling Pathway and Endocrine Resistance in Breast Cancer.
    Bai JW; Wei M; Li JW; Zhang GJ
    Front Pharmacol; 2020; 11():924. PubMed ID: 32636747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer.
    Li CL; Moi SH; Lin HS; Hou MF; Chen FM; Shih SL; Kan JY; Kao CN; Wu YC; Kao LC; Chen YH; Lee YC; Chiang CP
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.
    Haines CN; Wardell SE; McDonnell DP
    Essays Biochem; 2021 Dec; 65(6):985-1001. PubMed ID: 34328178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine therapy resistance: current status, possible mechanisms and overcoming strategies.
    Chang J; Fan W
    Anticancer Agents Med Chem; 2013 Mar; 13(3):464-75. PubMed ID: 22931419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
    Patel HK; Bihani T
    Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy.
    Rani A; Stebbing J; Giamas G; Murphy J
    Front Endocrinol (Lausanne); 2019; 10():245. PubMed ID: 31178825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer.
    Abdel-Hafiz HA
    Diseases; 2017 Jul; 5(3):. PubMed ID: 28933369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
    Lloyd MR; Wander SA; Hamilton E; Razavi P; Bardia A
    Ther Adv Med Oncol; 2022; 14():17588359221113694. PubMed ID: 35923930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecularly targeted endocrine therapies for breast cancer.
    Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Olayoku FR; Verhoog NJD; Louw A
    Front Pharmacol; 2023; 14():1122031. PubMed ID: 36992834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
    Brufsky AM; Dickler MN
    Oncologist; 2018 May; 23(5):528-539. PubMed ID: 29352052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer.
    Rodriguez D; Ramkairsingh M; Lin X; Kapoor A; Major P; Tang D
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?
    Ferro A; Generali D; Caffo O; Caldara A; De Lisi D; Dipasquale M; Lorenzi M; Monteverdi S; Fedele P; Ciribilli Y
    Semin Oncol; 2023; 50(3-5):90-101. PubMed ID: 37673696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance.
    Radhi S
    Prog Mol Biol Transl Sci; 2016; 144():539-562. PubMed ID: 27865467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
    Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic insight of drug resistance with special focus on iron in estrogen receptor positive breast cancer.
    Mittal R; Chaudhry N; Pathania S; Mukherjee TK
    Curr Pharm Biotechnol; 2014; 15(12):1141-57. PubMed ID: 25429654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.